Laboratory of America Holdings (Laboratory of America Holdings) GF Score : 81/100 (As of Apr. 27, 2024)

View and export this data going back to 1991. Start your Free Trial

What is Laboratory of America Holdings GF Score?

Laboratory of America Holdings has the GF Score of 81, which implies that the company might have Good outperformance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 7/10
3. Growth Rank : 5/10
4. GF Value Rank : 7/10
5. Momentum Rank : 8/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Laboratory of America Holdings might have Good outperformance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Laboratory of America Holdings's GF Score

For the Diagnostics & Research subindustry, Laboratory of America Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratory of America Holdings's GF Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Laboratory of America Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Laboratory of America Holdings's GF Score falls into.

Laboratory of America Holdings (NYSE:LH) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Laboratory of America Holdings GF Score Related Terms

Thank you for viewing the detailed overview of Laboratory of America Holdings's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratory of America Holdings (Laboratory of America Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Laboratory Corp of America Holdings (NYSE:LH) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

LH:Mexico L1CA34:Brazil

Address

358 South Main Street, Burlington, NC, USA, 27215

Website

https://www.labcorp.com

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Executives

Peter J Wilkinson	officer: SVP, Chief Accounting Officer	C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Kerrii B Anderson	director	WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D	officer: SVP, Global General Counsel	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman	director	6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber	officer: CEO, Covance Drug Development	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder	officer: EVP, President-Diagnostics Lab	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey	officer: EVP, Chief Strategy Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo	officer: EVP, Pres, Central Labs & Intl	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham	officer: EVP, CHRO	C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike	officer: Pres & CEO Clinical Business	C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Kirsten Marie Kliphouse	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg	officer: Chief Financial Officer, EVP	P O BOX 1017, CHARLOTTE NC 28201-1017
Brian J Caveney	officer: SVP, Chief Medical Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
R Sanders Williams	director	DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Amy B. Summy	officer: EVP, Chief Marketing Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215